This week’s On The Pen podcast unpacked major developments in obesity and metabolic health. New data from Harvard and Mass General suggest that nearly 70% of U.S. adults may qualify as having obesity when waist circumference is added to BMI. Dave also covered an emerging oral triple agonist with breakthrough absorption rates, promising early results from Fractal Health showing weight maintenance after GLP-1 discontinuation, and recent cash-pay price reductions for Zepbound. The episode also revisited Novo Nordisk’s Alzheimer’s trial, clarifying why the results weren’t the final word on GLP-1s in cognitive disease. Dave closed with personal insights on hunger signals after switching medications, plus updates on access, tools, and upcoming savings programs.